Preclinical Stage Partnering Terms and Agreements 2010 - 2015; New Report Launched

Market Research Reports, Inc. has announced the addition of “Preclinical Stage Partnering Terms and Agreements 2010-2015” research report to their website www.MarketResearchReports.com

Logo

Lewes, DE -- (SBWire) -- 12/09/2015 --The Preclinical Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Preclinical Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest preclinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2010 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities.

Chapter 1 provides an introduction to the report, whilst

Chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies.

Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

Chapter 5 provides a review of trends in preclinical stage deal making since 2010. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.

Chapter 7 provides a review of the leading preclinical stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2010 organized by stage of development – preclinical.

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2010.

In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

Benefits
Preclinical Stage Partnering Terms and Agreements 2010-2015 provides the reader with the following key benefits:
- In-depth understanding of preclinical stage deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
- Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of preclinical stage agreements with numerous real life case studies
- Identify leading preclinical stage deals by value since 2010
- Identify the most active preclinical stage dealmakers since 2010
- Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 2189 pages and 47 Figures "Preclinical Stage Partnering Terms and Agreements 2010-2015" report covers Executive Summary, Introduction, Why do companies partner preclinical stage compounds?, Preclinical stage deal strategies and structure, Preclinical stage partnering payment strategies, Trends in preclinical stage deal making, Average payment terms for preclinical stage partnering, Leading preclinical stage deals, Big pharma and big biotech preclinical stage partnering deals, Preclinical stage partnering contracts directory, Preclinical stage dealmaking directory, Appendix.

Find more information Visit at: http://www.marketresearchreports.com/current-partnering/preclinical-stage-partnering-terms-and-agreements-2010-2015

Find all Healthcare Report visit at - http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions

Media Relations Contact

Sudeep Chakravarty
GM - Operations
Market Research Reports, Inc
302-703-7787
http://www.marketresearchreports.com/current-partnering/preclinical-stage-partnering-terms-and-agreements-2010-2015

View this press release online at: http://rwire.com/648122